Clinical application of gelatin sponge microparticles combined with pirarubicin for hepatic transcatheter arterial chemoembolization in breast cancer liver metastasis treatment: results of a single-center long-term study
| Autor: | Ruo Yu Wang, Jian Ma, Song Liu, Guang Sheng Zhao, Jun Zhou, Yue Wei Zhang, Jianlin Wu, Ying Liu, Jie Bian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Carcinoma Hepatocellular RD1-811 Combination therapy Efficacy Pirarubicin Breast tumor Breast Neoplasms Gastroenterology Metastasis Breast cancer Internal medicine Medicine Humans Chemoembolization Therapeutic Transcatheter arterial chemoembolization Liver metastasis RC254-282 Retrospective Studies Absorbable gelatin sponge TACE business.industry Research Liver Neoplasms Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Prognosis Gelatin sponge microparticles Oncology Response Evaluation Criteria in Solid Tumors Doxorubicin Gelatin Surgery Female business medicine.drug Liver abscess |
| Zdroj: | World Journal of Surgical Oncology World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-8 (2021) |
| ISSN: | 1477-7819 |
| Popis: | Objective To retrospectively analyze the safety and long-term clinical efficacy of gelatin sponge microparticles combined with the chemotherapy drug pirarubicin for hepatic transcatheter arterial chemoembolization (GSMs-TACE) in order to treat breast cancer liver metastasis (BCLM). Methods Twenty-seven BCLM patients who underwent GSMs-TACE from July 2010 to July 2016 were enrolled. Tumor target blood vessels were slowly and regionally embolized with absorbable gelatin sponge particles and pirarubicin injections. Plain computed tomography (CT) scans and biochemical indexes were re-examined at 4 days after treatment, and enhanced CT scans or magnetic resonance images and biochemical indexes, 1 month later. For patients with stable tumors, the follow-up period was 2 to 3 months, and the tumor response was evaluated using Modified Response Evaluation Criteria in Solid Tumors. Adverse reactions, survival time, and prognostic factors were assessed. Results By October 2019, 27 patients with BCLM had undergone GSMs-TACE, with an average of 2.44 ± 1.58 treatments. The 1-, 3-, and 5-year survival rates were 62.96%, 22.22%, and 14.81%, respectively, and the mOS was 22.0 months. No serious complications, such as acute liver failure and liver abscess, had occurred. There were two cases of acute cholecystitis that recovered after symptomatic treatment. Multivariate analysis of the prognosis showed that the primary tumor size, number of metastatic lymph nodes, estrogen receptor/progesterone receptor (ER/PR) status, and time to postoperative liver metastasis and combination therapy were statistically significant. Conclusions The overall prognosis of BCLM was poor. GSMs-TACE was safe and effective for BCLM treatment and could prolong the median survival time of patients. Therefore, it is worthy of widespread clinical application. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink